Biarylpropylsulfonamides as Novel, Potent Potentiators of 2-Amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic Acid (AMPA) Receptors
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVLetterNEXTBiarylpropylsulfonamides as Novel, Potent Potentiators of 2-Amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic Acid (AMPA) ReceptorsPaul L. Ornstein, Dennis M. Zimmerman, M. Brian Arnold, Thomas J. Bleisch, Buddy Cantrell, Richard Simon, Hamideh Zarrinmayeh, S. Richard Baker, Mary Gates, Joseph P. Tizzano, David Bleakman, Allan Mandelzys, Kieth R. Jarvie, Ken Ho, Michelle Deverill, and Rajender K. KambojView Author Information Lilly Research Laboratories A Division of Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana 46285 NPS Allelix Corporation, 6850 Goreway Drive, Mississaugua, Ontario L4V 1V7, Canada Cite this: J. Med. Chem. 2000, 43, 23, 4354–4358Publication Date (Web):October 24, 2000Publication History Received29 June 2000Published online24 October 2000Published inissue 1 November 2000https://pubs.acs.org/doi/10.1021/jm0002836https://doi.org/10.1021/jm0002836rapid-communicationACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views1072Altmetric-Citations63LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Alkyls,Anions,Aromatic compounds,Receptors,Structure activity relationship Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other AMPAR PAMs, such as S18986, LY392098, and mibampator, which are thought to function by reducing desensitization of the ion channel [199]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [199]
Citations
Cites
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
Flip and Flop: A Cell-Specific Functional Switch in Glutamate-Operated Channels of the CNS
Sommer, B., Keinänen, K., Verdoorn, T. A., Wisden, W., Burnashev, N., Herb, A., Kohler, M., Takagi, T., Sakmann, B., & Seeburg, P. H. (1990) · Science · doi:10.1126/science.1699275 · Cited by 1,259
Yamada, K., & Tang, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-09-03904.1993 · Cited by 441
Neuropharmacology of AMPA and kainate receptors
Bleakman, D., & Lodge, D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00139-7 · Cited by 363
Self-citationLynch, G., Granger, R., Ambros-Ingerson, J., Davis, C. M., Kessler, M., & Schehr, R. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6447 · Cited by 160
Coding Channels in the Taste System of the Rat
Scott, T. R., & Giza, B. K. (1990) · Science · doi:10.1126/science.2171145 · Cited by 110
Granger, R., Staubli, U., Davis, M., Perez, Y., Nilsson, L., Rogers, G. A., & Lynch, G. (1993) · Synapse · doi:10.1002/syn.890150409 · Cited by 108
Facilitation of glutamate receptors reverses an age-associated memory impairment in rats
Granger, R., Deadwyler, S. A., Davis, M., Moskovitz, B., Kessler, M., Rogers, G. A., & LYNCH, G. S. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199604)22:4<332::aid-syn4>3.0.co;2-c · Cited by 101
Maneuf, Y. P., Crossman, A. R., & Brotchie, J. M. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199604)22:4<382::aid-syn9>3.0.co;2-7 · Cited by 62
Psychological effects of a drug that facilitates brain AMPA receptors
LYNCH, G. S., Kessler, M., Rogers, G. A., Ambros‐Ingerson, J., Granger, R., & Schehr, R. S. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00002 · Cited by 56
Research works printed but not linked: 9
- Ito I., 1990, J. Physiol., 424, 543
- Lee C. R., 1994, Drugs Aging, 4, 273
- Bertolino M., 1993, Recept. Channels, 1, 278
- Staubli U., 1994, Proc. Natl. Acad. Sci. U.S.A., 91, 781
- Zivkovic I., 1995, J. Pharmacol. Exp. Ther., 272, 309
- Thompson D. M., 1995, Proc. Natl. Acad. Sci. U.S.A., 92, 7671
- Fletcher E. J., 1995, Recept. Channels, 3, 31
- Well, Eugene, OR) for 60 min. Cells were washed with buffer solution and fluorescence measurements made using a Fluoroskan II fluorimeter (Labsystems
- Bleakman D., 1996, Mol. Pharmacol., 49, 585
Cited by
Cabré, A., Verdaguer, X., & Riera, A. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00496 · Cited by 477
Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00194-5 · Cited by 225
Self-citationAmpakines and the threefold path to cognitive enhancement
Lynch, G., & Gall, C. M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.007 · Cited by 174
Stabilization of protein-protein interactions in drug discovery
Andrei, S. A., Sijbesma, E., Hann, M., Davis, J., O’Mahony, G., Perry, M. W. D., Karawajczyk, A., Eickhoff, J., Brunsveld, L., Doveston, R. G., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1346608 · Cited by 163
Bai, F., Bergeron, M., & Nelson, D. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00104-7 · Cited by 144
AMPA receptor modulators as cognitive enhancers
LYNCH, G. S. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.09.009 · Cited by 136
Current perspectives on the development of non-biogenic amine-based antidepressants
Skolnick, P., Legutko, B., Li, X., & Bymaster, F. P. (2001) · Pharmacological Research · doi:10.1006/phrs.2000.0806 · Cited by 139
An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study
Maćkowiak, M., O’Neill, M. J., Hicks, C. A., Bleakman, D., & Skolnick, P. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00066-7 · Cited by 139
Self-citationBenzamide-Type AMPA Receptor Modulators Form Two Subfamilies with Distinct Modes of Action
Arai, A., Xia, Y., Rogers, G. A., LYNCH, G. S., & Kessler, M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040360 · Cited by 113
“, 1996), biarylsulfonamides (Ornstein et al., 2000; Linden et al., 2001), and D1 (Arai et al.”
BackgroundMurray, T. K., Whalley, K., Robinson, C. S., Ward, M., Hicks, C. A., Lodge, D., Vandergriff, J. L., Baumbarger, P. J., Siuda, E. R., Gates, M. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049445 · Cited by 107
“After the discovery that cyclothiazide and IDRA 21 could potentiate AMPA receptor activity, more potent and selective AMPA receptor potentiators have been discovered (Ornstein et al., 2000; Baumbarger et al., 2001b; Parsons et al., 2002).”
BackgroundSelf-citationLegutko, B., Li, X., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00006-5 · Cited by 112
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“Other AMPAR PAMs, such as S18986, LY392098, and mibampa-tor, which are thought to function by reducing desensitization of the ion channel [199], have been tested since the early 2000s for their potential applications in depression, schizophrenia, Parkinson ’ s disease, and attention de fi cit…”
MethodLead compounds discovered from libraries
Gołȩbiowski, A., Klopfenstein, S. R., & Portlock, D. E. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00203-9 · Cited by 105
AMPA Receptors as Therapeutic Targets for Neurological Disorders
Lee, K., Goodman, L., Fourie, C., Schenk, S., Leitch, B., & Montgomery, J. M. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.10.004 · Cited by 122
LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors
Quirk, J. C., & Nisenbaum, E. S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00228.x · Cited by 93
Dongbang, S., & Doyle, A. G. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09294 · Cited by 91
Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 107
Challenges for and current status of research into positive modulators of AMPA receptors
Ward, S. E., Bax, B. D., & Harries, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00726.x · Cited by 72
“Nonetheless, workers at Lilly have extensively described their chemical series which led to LY451395 and LY450108, and whose origin was identified by use of highthroughput screening technology against homomeric GluA4 (flip splice variant) using FLIPR technology (Figure 3) (Ornstein et al., 2000).”
MethodCarrigan, C. N., Bartlett, R. D., Esslinger, C. S., Cybulski, K. A., Tongcharoensirikul, P., Bridges, R. J., & Thompson, C. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010261z · Cited by 75
Structural Proof of a Dimeric Positive Modulator Bridging Two Identical AMPA Receptor-Binding Sites
Kaae, B. H., Harpsøe, K., Kastrup, J. S., Sanz, A. C., Pickering, D. S., Metzler, B., Clausen, R. P., Gajhede, M., Sauerberg, P., Liljefors, T., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.10.012 · Cited by 65
Kadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.027 · Cited by 62
O’Neill, M. J., Murray, T. K., Whalley, K., Ward, M., Hicks, C. A., Woodhouse, S., Osborne, D. J., & Skolnick, P. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.023 · Cited by 63
Li, F., Zou, X., & Wang, N. (2015) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201401013 · Cited by 59
5′-Alkyl-benzothiadiazides: A New Subgroup of AMPA Receptor Modulators with Improved Affinity
Phillips, D. P., Sonnenberg, J. D., Arai, A., Vaswani, R. G., Krutzik, P. O., Kleisli, T., Kessler, M., Granger, R., LYNCH, G. S., & Chamberlin, A. R. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00405-9 · Cited by 53
LY503430: Pharmacology, Pharmacokinetics, and Effects in Rodent Models of Parkinson's Disease
O'Neill, M. J., Murray, T. K., Clay, M. P., Lindstrom, T., Yang, C. R., & Nisenbaum, E. S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00037.x · Cited by 49
Marenco, S., & Weinberger, D. R. (2006) · CNS Drugs · doi:10.2165/00023210-200620030-00001 · Cited by 52
Modulation of glutamate receptors: Strategies for the development of novel antidepressants
Skolnick, P. (2002) · Amino Acids · doi:10.1007/s00726-001-0121-7 · Cited by 43
“LY392098, the prototypic biarylpropylsulfonamide described by Ornstein et al. (2000), manifests an antidepressant-like action in both mice and rats, significantly reducing the duration of immobility in the forced swim test (Fig.”
BackgroundGrove, S. J. A., Jamieson, C., Maclean, J. K. F., Morrow, J. A., & Ranković, Z. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000419 · Cited by 40
Timm, D. E., Benveniste, M., Weeks, A. M., Nisenbaum, E. S., & Partin, K. M. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070243 · Cited by 39
“Recent high-throughput screening assays have led to the development of a number of new positive allosteric modulators, including biarylsulfonamides (Ornstein et al., 2000; Miu et al., 2001), the series of amino indane sulfonamide derivatives (Ward and Harries, 2010; Ward et al.”
BackgroundGates, M. R., Ogden, A.-M., & Bleakman, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00040-5 · Cited by 38
Self-citationShepherd, T. A., Aikins, J. A., Bleakman, D., Cantrell, B. E., Rearick, J. P., Simon, R. L., Smith, E. C., Stephenson, G. A., Zimmerman, D. M., Mandelzys, A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0105474 · Cited by 36
Self-citationPotentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo
Vandergriff, J. L., Huff, K. D., Bond, A., & Lodge, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00031-4 · Cited by 37
Ahmed, A. H., Ptak, C. P., & Oswald, R. E. (2010) · Biochemistry · doi:10.1021/bi1000678 · Cited by 33
“without significantly disrupting the J helix or C subsite (57).”
BackgroundShaffer, C. L., Patel, N. C., Schwarz, J. B., Scialis, R. J., Wei, Y., Hou, X., Xie, L., Karki, K., Bryce, D. K., Osgood, S. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00300 · Cited by 34
Fowler, J. H., Whalley, K., Murray, T. K., O’Neill, M. J., & McCulloch, J. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000138665.25305.7c · Cited by 32
“A novel series of biarylpropylsulfonamide AMPA receptor potentiators has recently been developed (Ornstein et al., 2000), which are highly potent, selective, and centrally active (Linden et al.”
BackgroundZarrinmayeh, H., Bleakman, D., Gates, M. R., Yu, H. Y., Zimmerman, D. M., Ornstein, P. L., McKennon, T., Arnold, M. B., Wheeler, W. J., & Skolnick, P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000462n · Cited by 30
Self-citationBiaryl amide glucagon receptor antagonists
Kurukulasuriya, R., Sorensen, B. K., Link, J. T., Patel, J. R., Jae, H.-S., Winn, M., Rohde, J., Grihalde, N. D., Lin, C. W., Ogiela, C. A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.056 · Cited by 29
Cabré, A., Verdaguer, X., & Riéra, A. (2019) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201900748 · Cited by 28
Structural basis for positive allosteric modulation of AMPA and kainate receptors
Frydenvang, K., Pickering, D. S., & Kastrup, J. S. (2021) · The Journal of Physiology · doi:10.1113/jp280873 · Cited by 29
Linden, A.-M., Yu, H. Y., Zarrinmayeh, H., Wheeler, W. J., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00013-2 · Cited by 27
Self-citationPractical synthesis of pharmaceutically relevant molecules enriched in sp 3 character
Campbell, P. S., Jamieson, C. J., Simpson, I. D., & Watson, A. J. B. (2017) · Chemical Communications · doi:10.1039/c7cc08670a · Cited by 25
Molecular mechanisms of neurite growth with AMPA receptor potentiation
Voss, O. P., Milne, S. A., Sharkey, J., O’Neill, M. J., & McCulloch, J. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.09.001 · Cited by 25
Highly Enantioselective Iridium-Catalyzed Hydrogenation of 2-Aryl Allyl Phthalimides
Cabré, A., Romagnoli, E., Martínez-Balart, P., Verdaguer, X., & Riéra, A. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03865 · Cited by 26
Multiple Molecular Determinants for Allosteric Modulation of Alternatively Spliced AMPA Receptors
Quirk, J. C., & Nisenbaum, E. S. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10953.2003 · Cited by 25
“LY404187 showed that human GluR2i were preferentially sensitive to modulation compared with GluR2o ( Ornstein et al., 2000;”
Jordan, G. R., McCulloch, J., SHAHID, M., HILL, D., Henry, B., & Horsburgh, K. J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.011 · Cited by 26
Magnus, N. A., Aikins, J. A., Cronin, J. S., Diseroad, W. D., Hargis, A. D., LeTourneau, M. E., Parker, B. E., Reutzel‐Edens, S. M., Schafer, J. P., Staszak, M. A., et al. (2005) · Organic Process Research & Development · doi:10.1021/op0500741 · Cited by 24
A Fluorous-Tagged, Acid-Labile Protecting Group for the Synthesis of Carboxamides and Sulfonamides
Villard, A., Warrington, B. H., & Ladlow, M. (2004) · Journal of Combinatorial Chemistry · doi:10.1021/cc0499338 · Cited by 24
Patel, N. C., Schwarz, J. B., Hou, X., Hoover, D. J., Xie, L., Fliri, A. F. J., Gallaschun, R. J., Lazzaro, J. T., Bryce, D. K., Hoffmann, W. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401274b · Cited by 26
Seneci, P., & Miertuš, S. (2000) · Molecular Diversity · doi:10.1023/a:1013824317218 · Cited by 22
“Rather than creating another theoretical treaty about hypothetical projects and situations (which seldom occur in the real world ... ), three specific examples by scientists from Lilly and NPS Allelix [ 7 ], from The Mayo Clinic [8] and from The University of California [9] were selected to illustrate three of the abo…”
BackgroundMethod4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs
Manetti, D., Martini, E., Ghelardini, C., Dei, S., Galeotti, N., Guandalini, L., Romanelli, M. N., Scapecchi, S., Teodori, E., Bartolini, A., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00437-2 · Cited by 21
Ryder, J. W., Falcone, J. F., Manro, J. R., Svensson, K. A., & Merchant, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105734 · Cited by 18
“Among these, a new class of biarylpropylsulfonamides, represented by LY404187 and LY503430 act as potent and selective AMPA receptor potentiators (Ornstein et al., 2000, Miu et al., 2001; Quirk and Nisenbaum, 2002; Murray et al., 2003).”
BackgroundZarrinmayeh, H., Tromiczak, E. G., Zimmerman, D. M., Rankl, N. B., Ho, K. H., Domı́nguez, E., Castaño, A., Escribano, A., Fernandez, C., Jiménez, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.012 · Cited by 15
Self-citationArai, A., Xia, Y., Kessler, M., Phillips, D. P., Chamberlin, R., Granger, R., & LYNCH, G. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.566 · Cited by 15
“, 1998) and the biarylpropylsulfonamides (Ornstein et al., 2000).”
BackgroundLi, C., Bai, L., Ge, M.-T., Xia, A., Wang, Y., Qiu, Y.-R., & Xu, D. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02243a · Cited by 14
Harpsøe, K., Liljefors, T., & Balle, T. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.06.002 · Cited by 14
Ye, N., Wang, Q., Li, Y., & Zhen, X. (2024) · Medicinal Research Reviews · doi:10.1002/med.22086 · Cited by 18
“PF ‐ 04958242 (BIIB104) is a tetrahydrofuran ether ‐ based PAM of the AMPA receptor, that was originally developed by Pfizer from the published biarylpropylsulfonamide lead LY451646, 77 through rational and structure ‐ based drug design as depicted in Figure 10.”
Current development in sulfonamide derivatives to enable CNS-drug discovery
Blicharz-Futera, K., Kamiński, M., Grychowska, K., Canale, V., & Zajdel, P. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108076 · Cited by 13
Goodner, R. M., Brandes, D. S., Morais, G. N., Tao, Q., Tassone, J. P., Mercado, B. Q., Chen, S., & Ellman, J. A. (2024) · ACS Catalysis · doi:10.1021/acscatal.4c05866 · Cited by 11
Harpsøe, K., Varming, T., Gouliaev, A. H., Peters, D., & Liljefors, T. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2006.07.003 · Cited by 11
Rational Design of a Novel AMPA Receptor Modulator through a Hybridization Approach
Caldwell, N., Harms, J. E., Partin, K. M., & Jamieson, C. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5004553 · Cited by 10
Solid-Phase Preparation of a Library Based on a Phenylalanine Scaffold
Colombo, A., Fernàndez, J., de la Figuera, N., Fernández‐Forner, D., Forns, P., & Alberício, F. (2005) · QSAR & Combinatorial Science · doi:10.1002/qsar.200420105 · Cited by 9
Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice
Malá, H., Chen, Y., Worm, V. H., Kure, J., Kaae, B. H., Madsen, U., Badolo, L., Pickering, D. S., & Mogensen, J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.08.036 · Cited by 8
Synthesis of 14C‐labeled and tritiated AMPA potentiator LY450108
Czeskis, B. A., O'Bannon, D. D., Wheeler, W. J., & Clodfelter, D. K. (2004) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.899 · Cited by 8
Glutamate and Neurodegenerative Disease
Schaeffer, E., & Duplantier, A. J. (2010) · Topics in medicinal chemistry · doi:10.1007/7355_2010_11 · Cited by 9
Glutamatergic Approaches for the Treatment of Schizophrenia
Morrow, J. A., Gilfillan, R. F., & Neale, S. A. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00056 · Cited by 2
Antagonists of AMPA/KA and NMDA (glycine site) glutamate receptors
Кадиева, M. Г., Тоникович, О. Э., & Zefirova, O. H. (2008) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-008-0063-4 · Cited by 1
AMPA Receptor Positive Modulators
Morrow, J. A., Maclean, J. K. F., & Jamieson, C. (2012) · Wiley eBooks · doi:10.1002/9781118309421.ch7 · Cited by 2
Investigation of the Functional Effects of Two Novel Ampakines in the CNS
Jordan, G. R. (2007) · OpenGrey (Institut de l'Information Scientifique et Technique)
AMPA Receptor Positive Allosteric Modulators – a Case History
Ward, S. E. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735087-00105
Discovery and Clinical Data for a Novel AMPA Receptor Positive Modulator
Ward, S. E. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00099
Development of AMPA Receptor Modulators as Cognition Enhancers
Jamieson, C., & Duffy, E. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782629276-00310
Kolodiazhna, A. О., Faiziiev, O. O., & Kolodiazhna, O. O. (2024) · Ukrainica Bioorganica Acta · doi:10.15407/bioorganica2024.02.003
Kolodiazhna, A. О., Faiziiev, O. O., & Prysiazhnuk, D. V. (2026) · Reports of the National Academy of Sciences of Ukraine · doi:10.15407/dopovidi2026.02.075
BindingDB Entry 50014532: Biaryl amide glucagon receptor antagonists.
BindingDB (2009) · UC San Diego · doi:10.7270/q2xs5tth
β‐C(sp 3 )─H Arylation of Aliphatic Sulfonamides
Jurk, F., Sonsona, I. G., & van Gemmeren, M. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.6163847
β‐C(sp 3 )—H Arylierung Aliphatischer Sulfonamide
Jurk, F., Sonsona, I. G., & van Gemmeren, M. (2026) · Angewandte Chemie · doi:10.1002/ange.6163847
Positive Modulators of AMPA-Type Glutamate Receptors
LYNCH, G. S., & Gall, C. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-055-3_7
“The original compounds were benzamides, but work since then has resulted in benzothiadiazide (39), pyridothiadiazine (40), biarylpropylsulfonamide ( 41 ), and alkyl-benzothiadiazide (42) derivatives that all appear to be centrally effective (Fig. 1B).”
Background
Metadata
- Authors
- Ornstein, P. L., Zimmerman, D. M., Arnold, M. B., Bleisch, T. J., Cantrell, B., Simon, R., Zarrinmayeh, H., Baker, S. R., Gates, M., Tizzano, J. P., Bleakman, D., Mandelzys, A., Jarvie, K. R., Ho, K., Deverill, M., & Kamboj, R. K.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Ornstein, Paul L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-10-24
- Volume
- 43
- Issue
- 23
- Pages
- 4354-4358
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2014078988
- Cited by
- 77
- References
- 10
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2019: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 1 · 2013: 1 · 2012: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- AMPA receptor potentiators, isoxazolones, glutamate receptor agonists, neuroprotection, neurodegenerative diseases, sulfonamide derivatives, biaryls, structure-activity relationship
- MeSH terms
- Cell Line, Humans, Structure-Activity Relationship, Sulfonamides, Receptors, AMPA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.